L
Lytix Biopharma AS
F:6BG
Lytix Biopharma AS
F:6BG
Price:
0.894
EUR
-8.21%
Market Cap:
€544.1k
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
L
|
Lytix Biopharma AS
F:6BG
|
NO |
|
T
|
Tah Tong Textile Co Ltd
TWSE:1441
|
TW |
|
Cortina Holdings Ltd
SGX:C41
|
SG |
|
T
|
Thrace Plastics Holding and Commercial SA
ATHEX:PLAT
|
GR |
|
Cuckoo Homesys Co Ltd
KRX:284740
|
KR |
|
D
|
Dasheng Times Cultural Investment Co Ltd
SSE:600892
|
CN |
|
Suzlon Energy Ltd
NSE:SUZLON
|
IN |
|
Dongguan Aohai Technology Co Ltd
SZSE:002993
|
CN |
|
Thomson Medical Group Ltd
SGX:A50
|
SG |
|
C
|
Chrysos Corporation Ltd
OTC:CHRCF
|
AU |
|
Aoyama Zaisan Networks Co Ltd
TSE:8929
|
JP |
|
E
|
EcoFirst Consolidated Bhd
KLSE:ECOFIRS
|
MY |
|
Ascent Industries Co
NASDAQ:ACNT
|
US |
|
Roche Holding AG
OTC:RHHBY
|
CH |
|
K
|
Kyungdong Pharm
KOSDAQ:011040
|
KR |
|
R
|
Rayhoo Motor Dies Co Ltd
SZSE:002997
|
CN |
|
Forsee Power SA
PAR:FORSE
|
FR |
|
International Game Technology PLC
NYSE:IGT
|
UK |
|
G
|
Gold Lion Resources Inc
CNSX:GL
|
CA |
|
Allegheny Technologies Inc
NYSE:ATI
|
US |
|
BTB Real Estate Investment Trust
TSX:BTB.UN
|
CA |
Balance Sheet
Balance Sheet Decomposition
Lytix Biopharma AS
Lytix Biopharma AS
Balance Sheet Decomposition is not available for
Lytix Biopharma AS
Lytix Biopharma AS
Balance Sheet
Lytix Biopharma AS
Lytix Biopharma AS
Currency: NOK
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
35
|
50
|
13
|
29
|
197
|
95
|
27
|
131
|
|
| Cash Equivalents |
35
|
50
|
13
|
29
|
197
|
95
|
27
|
131
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
51
|
23
|
0
|
|
| Total Receivables |
12
|
9
|
5
|
4
|
6
|
7
|
13
|
13
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Assets |
47
|
59
|
17
|
33
|
203
|
152
|
63
|
144
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
3
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
47
N/A
|
59
+25%
|
17
-70%
|
33
+87%
|
203
+523%
|
153
-24%
|
63
-59%
|
147
+131%
|
|
| Liabilities | |||||||||
| Accounts Payable |
12
|
13
|
0
|
3
|
2
|
7
|
4
|
5
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
8
|
0
|
0
|
0
|
0
|
1
|
0
|
1
|
|
| Other Current Liabilities |
16
|
5
|
4
|
9
|
12
|
10
|
8
|
31
|
|
| Total Current Liabilities |
35
|
18
|
4
|
13
|
13
|
18
|
12
|
37
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
35
N/A
|
18
-50%
|
4
-78%
|
13
+226%
|
13
+5%
|
18
+37%
|
12
-34%
|
39
+220%
|
|
| Equity | |||||||||
| Common Stock |
1
|
2
|
2
|
3
|
4
|
4
|
4
|
7
|
|
| Additional Paid In Capital |
11
|
35
|
11
|
17
|
186
|
131
|
47
|
101
|
|
| Other Equity |
0
|
4
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
12
N/A
|
41
+248%
|
14
-67%
|
20
+46%
|
190
+853%
|
135
-29%
|
51
-62%
|
108
+110%
|
|
| Total Liabilities & Equity |
47
N/A
|
59
+25%
|
17
-70%
|
33
+87%
|
203
+523%
|
153
-24%
|
63
-59%
|
147
+131%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
39
|
39
|
39
|
39
|
39
|
41
|
41
|
68
|
|
Switch to:
Switch to:
See Also
Discover More
